Navigation Links
Barrett's esophagus carries lower risk of malignancy than previously reported
Date:6/16/2011

Patients with Barrett's esophagus may have a lower risk of esophageal cancer than previously reported, according to a large, long-term study published online June 16 in the Journal of the National Cancer Institute.

Barrett's esophagus is a premalignant condition, and patients who have it are often advised to have regular endoscopies to watch for signs of esophageal adenocarcinoma, the most common kind of esophageal cancer in many parts of the world. But how often Barrett's esophagus progresses to cancer has not been clear. Previous estimates of the rate of progression have varied widely.

In this study, Shivaram Bhat, B.Ch., MRCP, of Queens University Belfast and colleagues prospectively followed 8,522 patients in the Northern Ireland Barrett's Esophagus Registry, one of the largest registries in the world of people with the condition. After an average follow-up time of 7 years, 79 patients were diagnosed with esophageal cancer, 16 with cancer of the gastric cardia (the part of the stomach closest to the esophagus), and 36 with precancerous changes known as high-grade dysplasia. In the entire group, the incidence of these three conditions combined was 0.22% per year. Previous studies have reported an incidence of cancer among people with Barrett's esophagus between 0.58% and 3% per year.

The researchers also looked at the incidence of cancer and high-grade dysplasia in different subgroups of patients. Men were statistically significantly more likely to progress to malignancy than women, and people age 60-69 had a higher risk than those under 50 or those age 80 and over. The highest rates of progression were among patients with low-grade dysplasia (1.40%) or specialized intestinal metaplasia (0.38%) at their initial endoscopy and biopsy.

The authors conclude that the risk of Barrett's esophagus progressing to esophageal cancer is less than previously reported and that this finding has implications for clinical practic
'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cancer Risk With Barretts Esophagus May Be Lower Than Thought
2. Long-term follow-up shows multipolar electrocoagulation ablation effective for Barretts esophagus
3. An international study in China finds strawberries may slow precancerous growth in the esophagus
4. Treatment of Barretts esophagus may lower risk of esophageal cancer
5. Watchful waiting no longer recommended for some high-risk Barretts esophagus patients
6. Extremely obese children have 40 percent higher risk of reflux disease of esophagus
7. New endoscopic treatment may spare Barretts esophagus patients from surgery
8. Prolonging life carries more weight
9. Nationwide Health Information Network now carries public health data
10. Proton therapy carries precise, potent punch against childrens cancers
11. Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... A new study has found that following a healthy ... the metabolic syndrome. Published early online in CANCER ... the findings indicate that children with cancer and adults ... information about how their lifestyle may influence their long-term ... are known to be at increased risk for the ...
(Date:7/28/2014)... July 28, 2014 According to the Greek ... is a comprehensive fitness guide that teaches men how to ... , Vkool reveals in its review that inside the ... Ways to gain the maximum muscle fiber ... build muscle and avoid fat gain , Ways ...
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... 2014 CW4K was among those invited ... Obama and Partnership for a Healthier America ... the group's DrinkUP effort, which encourages people ... , The seven organizations added included Brita®, First ... S’well Bottle, Santa Clara Valley Water District and The ...
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 Footwear ... gorgeous shoes styles from Mephisto. With shoes, sandals, and ... years, Mephisto products continually provide handmade comfort shoes ... men and women have come to rely on the ... , Mephisto shoes and sandals contain the highest ...
Breaking Medicine News(10 mins):Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3
... breast cancer test, which could save several women from needless ... core needle biopsy to sample suspect breast tissue for microscopic ... of gene patterns in the sample. This may help in ... test has very little proof. ,Till date, the ...
... or MRSA, a type of bacteria resistant to treatment, is ... direct contact and can spark off skin infections in normal ... to be dormant in nearly 2.3 million Americans with no ... crucial to identify the carriers of the illness and treat ...
... began a two-day meeting here Sunday over ways to ... region. ,Bangladesh Prime Minister Khaleda Zia inaugurated ... enduring cooperation in the region to make healthcare available ... ways to make more efficient use of whatever resources ...
... throng the Mahim beach to drink sweet seawater for ... against drinking// the polluted water. ,Scientists clarified ... natural phenomenon of dilution. ,"Dilution is a ... during the southwest monsoon and occurs when rainwater borne ...
... of robotic technology and auditory signals.// ,Finding ... to before will be quite tough. Then you can ... people. System for Wearable Audio Navigation (SWAN) is designed ... find their way in unknown territory, particularly when vision ...
... would seek help from pharmacies in order to screen patients ... said that the current scheme in which the ministry's hospitals ... buy drugs at pharmacies. ,"Pharmacists at the drugstores ... If they are found to have contacted sick or dead ...
Cached Medicine News:Health News:Novel test for diagnosis of breast cancer 2Health News:Maharashtra warns against Mahim's 'miracle' water 2Health News:SWAN system for navigation 2Health News:SWAN system for navigation 3Health News:SWAN system for navigation 4
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Medicine Products: